Head to Head Comparison: Predictive Oncology (NASDAQ:AGPU) versus Bioventus (NASDAQ:BVS)

Bioventus (NASDAQ:BVS) and Predictive Oncology (NASDAQ:AGPU) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

62.9% of Bioventus shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Bioventus has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bioventus and Predictive Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	3	1	3.00
Predictive Oncology	1	0	0	0	1.00

Bioventus presently has a consensus target price of $14.00, indicating a potential upside of 56.25%. Given Bioventus’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Bioventus is more favorable than Predictive Oncology.

Earnings and Valuation

This table compares Bioventus and Predictive Oncology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09 million	1.31	$22.73 million	$0.33	27.15
Predictive Oncology	$1.62 million	3.08	-$12.66 million	($13.50)	-0.11

Bioventus has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bioventus and Predictive Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	4.00%	28.88%	8.53%
Predictive Oncology	-5,065.23%	N/A	-235.55%

Summary

Bioventus beats Predictive Oncology on 13 of the 15 factors compared between the two stocks.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About Predictive Oncology

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.